GE Healthcare is looking to double the current annual sales of $2.4 billion in its molecular imaging business segment in the next three to five years.
According to a report in Bloomberg Businessweek, John Dineen, CEO of GE Healthcare, told a Goldman Sachs Group conference in Boston this week that approximately 20% of the division's research budget is earmarked for molecular imaging.
Dineen said that GE plans to expand its molecular imaging-related businesses with research and development, partnerships, and acquisitions of less than $1 billion each, such as GE's 2010 acquisition of Clarient for $580 million.
